Belite Bio Revenue and Competitors
Estimated Revenue & Valuation
- Belite Bio's estimated annual revenue is currently $2.8M per year.
- Belite Bio's estimated revenue per employee is $155,000
Employee Data
- Belite Bio has 18 Employees.
- Belite Bio grew their employee count by 6% last year.
Belite Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | Clinical Project Manager | Reveal Email/Phone |
Belite Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Belite Bio?
Belite Bio Inc is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. Developed from our anti-RBP4 technology platform, our lead candidate, LBS-008, is currently in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Status in the US and Europe, as well as Rare Pediatric Disease Status in the US.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.5M | 18 | -18% | N/A |
#2 | $2.8M | 18 | 6% | N/A |
#3 | $15M | 18 | 0% | $67.5M |
#4 | $2.4M | 18 | N/A | N/A |
#5 | $1.6M | 18 | -5% | N/A |